Show/hide subitems Explore Cell Line Engineering Knockout Knock-in Bioproduction cell engineering Pin-point™ Base Editing Services Contract Research Services Custom Reference Standards Custom Oligonucleotides Custom Libraries Show/hide subitems Explore Cell Panel Screening 2D OncoSignature 2D OncoSignature Long-term assay 3D OncoSignature Custom screens Cell Line Engineering Show/hide subitems Explore Immune Cell Screening CRISPR immune cell screens Custom immune cell screens Compound screening assays iTreg Polarization assay iTreg Suppression assay T Cell Activation assay Mixed Lymphocyte Reaction assay Complement-dependent cytotoxicity assay Cell Panel Screening Show/hide subitems Explore Functional Genomic Screening Arrayed screens Pooled screens CRISPR screens RNAi screens Single-cell CRISPR screens Immune cell screens Pin-point base editing Immune Cell Screening Show/hide subitems Explore Bioproduction Cell Lines CHOSOURCE™ expression platform CHOSOURCE™ TnT transposon technology Transfection & Ancillary Reagents Non-mammalian research Show/hide subitems Explore Downstream Analysis Western blotting supplies Cellular imaging reagents Luminescence assays Fluorescent nucleotides & haptens Microplates Bioproduction Cell Lines Show/hide subitems Explore Libraries CRISPR libraries RNAi libraries Cherry-pick library tool - clones Cherry-pick library tool - synthetic Downstream Analysis Show/hide subitems Explore Reference Standards Create your own reference standard Oncospan Analysis technique Sample type Format Libraries
Show/hide subitems Explore Custom Oligonucleotides Single-strand RNA synthesis Custom siRNA Custom antisense oligonucleotides Custom DNA Custom microRNA Reference Standards Show/hide subitems Explore Engineered Cell Models Build your own cell line Knockout cell lines Cancer related cell lines Cas9 stable cell lines dCas9 stable cell lines Custom Oligonucleotides Show/hide subitems Explore Gene Expression CRISPRa cDNA & ORFs Engineered Cell Models Show/hide subitems Explore CRISPR Modulation CRISPRi CRISPRa CRISPRa libraries dCas9 stable cell lines Controls Gene Expression Show/hide subitems Explore Gene Knockdown siRNA shRNA microRNA Controls lncRNA Custom siRNA design Cherry-pick library tool - synthetic Cherry-pick library tool - clones RNAi libraries CRISPR Modulation Show/hide subitems Explore Gene Editing CRISPR guide RNA Cas9 nucleases Controls Custom guide RNA Knock-in templates Cherry-pick library tool - clones Cherry-pick library tool - synthetic CRISPR libraries Gene Knockdown To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom.Pin-point™ Base Editing Platform All Dharmacon™ Reagents Gene Editing CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
A copy of the presentation will be available at once the presentation concludes.ĬRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The data are embargoed until the beginning of the Drug Development Special Track Session: New Drugs on the Horizon: Part 1 at 1:00 p.m. Location: Tangerine Ballroom 2, Convention Centerĭate and Time: April 16, 2023, 1:25 – 1:40 p.m. Session Title: New Drugs on the Horizon: Part 1 Session Type: Drug Development Special Track Session Title: CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors ZUG, Switzerland and BOSTON, Ma(GLOBE NEWSWIRE) - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation of preclinical data at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place April 14 – 19, 2023, in Orlando, FL.
0 kommentar(er)
